Scinai shares rise 20.17% premarket ahead of AGM and lower-than-industry CEO compensation.

Scinai Immunotherapeutics surged 20.17% in premarket trading following the announcement of its Annual General Meeting on December 22nd, where shareholders will vote on CEO Amir Reichman’s compensation. The news highlighted that Reichman’s total pay of $659,000—a 29% decrease from 2023—was 47% below the industry average, with salary accounting for 51% of his compensation. Analysts noted this aligns with the company’s strong three-year EPS growth of 85% despite a 97% shareholder loss, suggesting cost discipline and potential for management accountability. The upcoming AGM, combined with the CEO’s below-industry pay, likely spurred optimism among investors anticipating governance improvements.